18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma | Zendy

Martin J. Shelly | Zendy; Shaunagh McDermott | Zendy; Owen J. O’Connor | Zendy; Michael A. Blake | Zendy

Open Access

18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma

Author(s) -

Martin J. Shelly,

Shaunagh McDermott,

Owen J. O’Connor,

Michael A. Blake

Publication year - 2012

Publication title -

isrn hematology

Language(s) - English

Resource type - Journals

eISSN - 2090-4428

pISSN - 2090-441X

DOI - 10.5402/2012/456706

Subject(s) - medicine , lymphoma , positron emission tomography , radiology , fluorodeoxyglucose , nuclear medicine , follicular lymphoma , positron emission tomography computed tomography , stage (stratigraphy) , radiation therapy , computed tomography , pathology , paleontology , biology

18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for posttreatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research